The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...

People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

When her consultant offered 20st Sarah a brand new injection called Ozempic that promised to treat her diabetes and help her ...

Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...